Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | IRAK4 | Q9NWZ3 | 8/20 | 0.41 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25338234 | 0.90 | TGFBR1 (0.46) | TGFBR1KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL21997350 | 0.87 | TGFBR1 (0.44) | TGFBR1KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL30267093 | 0.87 | TGFBR1 (0.44) | TGFBR1KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL25339924 | 0.86 | SMPD3 (0.49) | TGFBR1KDM4ENPC1RAB9AIRAK4 | |
| SCHEMBL18208222 | 0.86 | SMPD3 (0.52) | TGFBR1KDM4ENPC1RAB9AIRAK4 | |
| SCHEMBL21998169 | 0.86 | TGFBR1 (0.45) | TGFBR1KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL21998032 | 0.85 | SMPD3 (0.53) | TGFBR1KDM4ENPC1RAB9AIRAK4 | |
| SCHEMBL21997182 | 0.84 | IRAK4 (0.41) | TGFBR1KDM4ENPC1RAB9AHSD17B10 | |
| SCHEMBL25338786 | 0.84 | IRAK4 (0.45) | IRAK4JAK2NTRK1 | |
| SCHEMBL21998201 | 0.84 | IRAK4 (0.48) | TGFBR1IRAK4JAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-01-09 | — | — | US | disclosed |
| EP-4472967-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| US-12091411-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-11-16 | — | — | US | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
| WO-2023147594-A2 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230365562-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885KDM4E 190/4885NPC1 3159/4885 |
| US-20250011325-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885KDM4E 190/4885NPC1 3159/4885 |
| US-12091411-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TGFBR1 1014/4885KDM4E 190/4885NPC1 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.